Varicose Veins Treatment Market Size & Growth Forecast 2026–2035, By Segments (Type, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Varicose Veins Treatment Market size was around USD 1.5 Billion in 2025 and is slated to grow at a 6.5% CAGR from 2026 to 2035, crossing USD 2.82 Billion by 2035. The industry revenue for 2026 is calculated at USD 1.59 billion.

• Base Year Value (2025): USD 1.5 Billion
• CAGR (2026-2035): 6.5%
• Forecast Year Value (2035): USD 2.82 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Varicose Veins Treatment Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 47.28% market share in 2025, supported by high procedural volumes, broad access to minimally invasive therapies, and efficient clinical referral pathways.
  • Asia Pacific is projected to expand at a 7.35% CAGR, driven by improving access to vascular care, earlier diagnosis, greater availability of minimally invasive treatments, and expanding outpatient services.

• Segment Momentum:

  • It holds 66.45% share due to widespread clinical familiarity, routine outpatient use, and established effectiveness across a broad range of visible vein conditions.
  • It is growing fastest due to increasing preference for minimally invasive procedures that improve efficiency, enable same-day treatment, and align with modern outpatient care models.

• Market Expansion Drivers:

  • Rising sedentary lifestyles and aging population increasing prevalence of venous disorders.
  • Growing adoption of minimally invasive endovenous and laser treatment procedures.
  • Advancements in outpatient vascular treatment centers improving accessibility and recovery outcomes.

• Leading Market Participants:

  Prominent players in the varicose veins treatment market include Medtronic plc (Ireland), AngioDynamics, Inc. (United States), Lumenis Be Ltd. (Israel), Alma Lasers Ltd. (Israel), Sciton, Inc. (United States), Quanta System S.p.A. (Italy), Dornier MedTech GmbH (Germany), intros Medical Laser GmbH (Germany), Theraclion SA (France), Biolitec AG (Germany).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.5 Billion
  • Projected Market Size: USD 2.82 Billion by 2035
  • Growth Forecasts: 6.5% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Injection Sclerotherapy (Type) | Hospitals (End-use)
  • Emerging Opportunity Segment: Endovenous Ablation (Type) | Ambulatory Surgical Centers (End-use)

Market Growth Drivers and Industry Trends

Rising sedentary lifestyles and aging population increasing prevalence of venous disorders

Long periods of sitting or standing, combined with age-related weakening of venous valves and vessel walls, are steadily enlarging the treatable patient pool for the varicose veins treatment market. This trend does not only increase diagnosis volumes; it also changes care-seeking behavior, as symptoms such as leg heaviness, swelling, visible vein enlargement, and recurrent discomfort are more likely to interfere with daily mobility in older adults and working populations with low physical activity. As physicians encounter venous insufficiency earlier and more frequently in routine practice, referral flows into procedural care strengthen, aiding market expansion for compression-based management, sclerotherapy, ablation, and follow-up vascular services.

Growing adoption of minimally invasive endovenous and laser treatment procedures

The varicose veins treatment market is being shaped by a clear preference for procedures that reduce pain, scarring, downtime, and hospital dependence compared with conventional vein stripping. Endovenous ablation and laser-based approaches fit well with physician and patient expectations for faster recovery and lower disruption to work and daily life, which increases acceptance of interventional treatment at earlier stages of disease progression. This practical advantage also influences provider investment decisions, as clinics and specialists prioritize technologies that allow efficient patient throughput, repeatable procedural workflows, and office-based delivery, reinforcing market demand for device platforms, consumables, and image-guided treatment capabilities.

Advancements in outpatient vascular treatment centers improving accessibility and recovery outcomes

The expansion and modernization of outpatient vascular treatment centers is making varicose vein care easier to access, more operationally efficient, and better aligned with how these procedures are now delivered. For the varicose veins treatment market, this matters because patients can move from consultation to imaging, intervention, and short-term follow-up without requiring inpatient infrastructure, lowering practical barriers to treatment and increasing market adoption among individuals who might otherwise delay care. Improved recovery protocols, dedicated vein specialists, and streamlined scheduling also support more consistent outcomes and patient satisfaction, which in practice strengthens referral momentum and encourages broader adoption of procedural treatment pathways.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising sedentary lifestyles and aging population increasing prevalence of venous disorders	2.20%	Moderate	North America, Europe, Asia Pacific	High	Near Term
Growing adoption of minimally invasive endovenous and laser treatment procedures	2.40%	High	North America, Europe	High	Near Term
Advancements in outpatient vascular treatment centers improving accessibility and recovery outcomes	1.80%	Moderate	North America, Europe, Middle East & Africa	High	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional position in 2025, accounting for a 47.28% share of the varicose veins treatment market. This leadership is supported by strong procedural volumes, broad availability of minimally invasive treatment options, and established clinical pathways that move patients from diagnosis to outpatient intervention efficiently. The region’s market activity is also supported by higher patient awareness and routine specialist referral patterns, which help convert symptomatic cases into treated cases rather than prolonged observation.

Asia Pacific is projected to expand at a 7.35% CAGR over the forecast period in the varicose veins treatment market, driven by rising treatment uptake as access to vascular care and modern vein procedures improves across more urban healthcare settings. Growth is being fueled by a practical shift toward earlier diagnosis and intervention, alongside increasing availability of less invasive therapies that fit outpatient and day-care treatment models. As providers broaden service capacity and more patients seek treatment for both medical and functional reasons, procedure demand is accelerating across the region.

Key Country Insights

United States

Minimally Invasive Care

The U.S. varicose veins treatment market increasingly favors minimally invasive procedures supported by advanced imaging and outpatient care. Healthcare providers in the U.S. continue expanding access to endovenous therapies that improve patient convenience and recovery.

Japan

Outpatient Procedure Adoption

Japan continues expanding outpatient treatment options for varicose veins as healthcare providers seek efficient patient management. Hospitals and specialty clinics in Japan increasingly utilize minimally invasive procedures that reduce recovery time and improve treatment accessibility.

South Korea

Advanced Vein Procedures

South Korea combines modern vascular treatment technologies with specialized clinical services for varicose veins management. Providers in South Korea increasingly adopt image-guided minimally invasive procedures that enhance treatment precision and patient experience.

Germany

Precision Treatment Standards

Germany prioritizes clinically validated varicose veins treatment technologies that support accurate diagnosis and effective intervention. Healthcare providers in Germany increasingly adopt minimally invasive techniques while maintaining high procedural quality standards.

France

Integrated Vascular Care

France emphasizes coordinated vascular care supported by modern diagnostic capabilities and minimally invasive treatment options. Healthcare providers in France continue strengthening patient pathways that improve procedural efficiency and long-term vein health management.

Italy

Specialist Clinic Expansion

Italy supports wider adoption of advanced varicose veins treatment through specialized vascular clinics and modern therapeutic techniques. Healthcare providers in Italy increasingly focus on efficient outpatient procedures that improve patient comfort and clinical outcomes.

Segment Leadership and Growth Trends

  Type Segment Analysis: Injection Sclerotherapy (Largest Segment) vs Endovenous Ablation (Fastest-Growing Segment)

Injection Sclerotherapy held a 66.45% share of the varicose veins treatment market in 2025, reflecting its established role as a widely used treatment option across routine clinical settings. its position is supported by broad physician familiarity, consistent use in managing a wide range of visible vein conditions, and straightforward integration into standard outpatient vein care. The segment’s strong share in the varicose veins treatment market also benefits from its long-standing adoption pattern, which helps sustain procedure volumes through regular patient flow and repeat clinical preference.

Endovenous Ablation is emerging as the fastest-growing segment in the varicose veins treatment market because treatment pathways are increasingly shifting toward minimally invasive approaches that address venous insufficiency with procedural efficiency. Its momentum is tied to growing acceptance among providers seeking targeted interventions that fit modern vein treatment workflows while offering an alternative to more conventional methods. Compared with other treatment types, Endovenous Ablation is gaining traction as clinical practices align more closely with less invasive procedural models and evolving patient management preferences.

End-use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)

Hospitals accounted for the largest share of the varicose veins treatment market in 2025, supported by their ability to manage a broad mix of patient cases within integrated care environments. Their leading share is sustained by access to specialist teams, diagnostic capabilities, and procedural infrastructure that allow hospitals to handle both standard and more complex vein treatment requirements. This setting remains central to the varicose veins treatment market because many patients enter treatment pathways through hospital-based referral and evaluation systems.

Ambulatory Surgical Centers are the fastest-growing end-use segment in the varicose veins treatment market as providers increasingly favor efficient outpatient settings for procedures that do not require extended hospital stays. Their growth is being supported by the practical shift toward streamlined same-day treatment models, especially for minimally invasive vein procedures that can be performed with lower operational burden. Relative to hospitals and other care settings, Ambulatory Surgical Centers are gaining momentum because they align well with procedure standardization and the broader move toward outpatient specialty care.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Endovenous Ablation, Injection Sclerotherapy, Surgical Ligation & Stripping	Injection Sclerotherapy	Endovenous Ablation
End-use	Hospitals, Ambulatory Surgical Centers, Specialty Clinics	Hospitals	Ambulatory Surgical Centers

Competitive Landscape and Market Positioning

Leading companies in the varicose veins treatment market:

1. Medtronic plc (Ireland)

2. AngioDynamics Inc. (United States)

3. Lumenis Be Ltd. (Israel)

4. Alma Lasers Ltd. (Israel)

5. Sciton Inc. (United States)

6. Quanta System S.p.A. (Italy)

7. Dornier MedTech GmbH (Germany)

8. intros Medical Laser GmbH (Germany)

9. Theraclion SA (France)

10. Biolitec AG (Germany)

Minimally invasive medical procedures are reshaping treatment approaches for venous disorders. The varicose veins treatment market is evolving through improved laser and radiofrequency-based therapeutic methods. Continuous advancements in procedural precision are enhancing recovery outcomes and patient comfort.

Industry Development/News

Company Name	Date	Key Development
Avis Hospital	May-26	Avis Hospital secured a $2.5 million investment from NABVENTURES, supported by Equity 360, to scale its specialized varicose veins treatment operations. This capital infusion is earmarked for expanding clinical infrastructure and enhancing access to advanced vascular care services specifically within rural regions of India, addressing a critical gap in service delivery.
Aakash Healthcare	May-26	Aakash Healthcare partnered with Medtronic to launch a dedicated vein clinic in Dwarka, marking the first facility of its kind in North India. This collaboration integrates specialized clinical expertise with advanced medical technology to provide comprehensive treatment solutions, reflecting a strategic expansion in regional vascular care capacity and specialized medical service offerings.
WONTECH	May-26	WONTECH established its Southeast Asia regional headquarters in Thailand, designated as WONTECH ASIA. This expansion serves to consolidate the company’s regional operations and provides a strategic hub for accelerating the deployment and support of its medical technology solutions, including those utilized in vascular and aesthetic treatment procedures throughout the region.
Koninklijke Philips N.V.	Jun-24	Koninklijke Philips N.V. introduced the Duo stent, which received FDA approval for the treatment of patients suffering from chronic venous insufficiency (CVI) resulting in blood flow blockage. This product launch represents a material technological advancement in venous management, providing clinicians with a new interventional capability to address persistent venous obstruction and improve patient outcomes.
VVT Medical	Jan-24	VVT Medical finalized a strategic distribution partnership with Methapharm Inc. to commercialize its ScleroSafe platform within the United States. This agreement effectively expands VVT Medical’s reach into the North American market, leveraging Methapharm’s distribution infrastructure to increase the availability of its non-invasive varicose vein treatment technology to clinical providers.
Theraclion	Jun-23	Theraclion received U.S. FDA approval to initiate a pivotal clinical study evaluating the efficacy of its Sonovein system for treating primary insufficiency of the great saphenous veins. This development is a critical step in the regulatory and commercialization roadmap for its non-invasive therapeutic technology, aiming to validate its clinical utility in treating venous disease.